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ABSTRACT   
Begin basal cell carcinoma (BCC) is most common skin cancer over the world. There are around 20 modalities 
for BCC treatment. Laser surgery is uncommon option. We demonstrate our long term follow up results.  
Aim: To evaluate long term efficacy of a 980nm diode laser for the difficult-to-treat basal cell carcinoma. 
Materials and Methods: 167 patients with 173 basal cell carcinoma on the nose were treated with a 980 nm 
diode laser from May 1999 till May 2005 at Latvian Oncology center. All tumors were morphologically 
confirmed. 156 patients were followed for more than 5 years. 
Results: The lowest recurrence rate was observed in cases of superficial BCC, diameter<6mm; bet the highest 
recurrence rate was in cases of infiltrative BCC and nodular recurrent BCC.  
Conclusions: 980 nm diode laser is useful tool in dermatology with high long term efficacy, good acceptance 
by the patients and good cosmetics results. 
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1. INTRODUCTION  
Basal cell carcinoma (BCC) is most common skin cancer over the world and affect all adults of either gender.  
BCC is a skin cancer derived from nonkeratinizing cells that form the basal layer of the epidermis. BCC is a non-
melanocytic skin cancer with very slow growth tendency, small mortality and high risk of recurrence. BCC typically 
appears on sun-exposed skin (face, neck) of lighter-skinned individuals, with approximately 30% occurring on the nose. 
BCC has high recurrence rate – up to 40% depending on localization, size, histological subtype of tumor and other 
factors. There are high recurrence zones on the faces – nose, ear, lips and eyelid. With increasing sizes (more than 6mm), 
tumor recurred more frequently. Infiltrative forms recur more frequently as compared to nodular or superficial form. It is 
possible that recurrent tumor recur more aggressively. Metastasis of BCC occurs rarely, with rates from 0.0028% to 
0.55% [1]. 
The most significant guidelines for BCC management are National Comprehensive Cancer Network Guidelines 
& Clinical Resources, British Association of Dermatology guidelines and Cochrane review interventions for basal cell 
carcinoma of the skin. The first goal of skin cancer management is complete cure of the BCC. Secondary goals are 
preservation of normal tissue, preservation of function, and optimal cosmetic results[2-4]. 
There are different treatment modalities (about 20). There are difficult-to-treat places on the face – eyelids, lips, eyes and 
nose [5]. Ways of ВСС treatment: surgery (including Moh’s micrographic surgery (ММS), operation with postoperative 
margin assessment (POMA) and curettage), radiotherapy, cryosurgery, laser surgery, photodynamic therapy and 
imunomodulators.Each method has positive and negative aspects.   
ММS is the “gold standard” for BCC treatment in countries where it is possible. POMA and ММS enables to control the 













However, operation in case of BCC needs a retreat of 3-5 mm from healthy skin which may result in difficulties 
to close the wound. This complicates the operation and demands transplantation of skin, which can reduce the cosmetic 
result (scars are possible).  Such surgical procedures are done in the hospital, sometimes using general anesthesia, which 
significantly increases postoperative period. Besides, patients may have contraindications towards operation (myocardial 
infarction, cerebrovascular accident, use of anticoagulants and other). Radiotherapy is not used for patients until the age 
of 50-60 as it can induce new and more complicated tumor after 20-30 years. Radiotherapy needs 12-15 procedures (3 
weeks) and 3-5 weeks for wound healing. Radiotherapy very often complicates with skin inflammation what reduces the 
quality of life. Cryosurgery  is another treatment option, but is painful procedure. Face edema is possible after this 
treatment for one week. Wound heals with inflammation, sometimes with suppuration. Postoperative period lasts for 3-4 
weeks.  Treatment with imunomodulators is also a long procedure – 4 to 6 weeks or even longer. Face edema can be 
present and painful. Wound can heal with inflammation, sometimes with pus. 
Laser surgery is uncommon form of treatment, although the interest to laser surgery increases [6]. Laser surgery 
can be done in an outpatient unit what is a main advantage in compares to other treatment options . Local anesthesia is 
used and the operation lasts 2-3 times faster than ROMA, which reduces complications in postoperative period and 
ensures good cosmetic results, increasing the satisfaction of patient. Historically СО2 and Nd:YAG lasers are used [7,8]. 
However they have many limitations. In past 10-15 years diode lasers have developed a lot. Although primary results 
were very promising  [9-12] data on long-term studies are not available [13]. 
   Efficiency analysis of laser surgery in case of ВСС in difficult localizations (on nose) is analyzed in this work. 
Term “efficiency” in this work has been analyzed from two perspectives:  1) the number of residual tumors that have 
found in 6 months after the treatment; 2) number of recurrences. As BCC recurrence developed over many years with 
30% in the first year, 50% - second year and up to 66% in the third year - this work incudes observations for results over 







     To evaluate long term efficiency of BCC laser treatment for difficult-to-treat tumors in nose region.   
3. Methods and Patients 
      Retrospective, descriptive, non-comparative, single institution study was performed. According to Latvian 
Cancer registry and medical documentation of Latvian Oncology center (LOC) we collected information about patients 
treated with laser. 167 patients with 173 BCC on the nose were treated with the 980nm diode laser from May 1999 till 
May 2005 in Outpatient department of LOC. Analysis on illness treatment and further illness history was performed 
from the moment of occurrence until 31.12.2012.We collected information about age, gender, localization of tumor, 
histological types, treatment modalities (power, continues or pulse type, bare fiber type), complication – operation pain, 
inflammation, postoperative course for each patient and history of live for more than 5 years (live or dead, recurrence 
rate).  All tumors were morphologically confirmed by histological or cytological examination. Informed consent was 
obtained from all patients. The inclusion criteria were age from 18 years, basal cell carcinoma - T1-T2N0M0. Patients 
with follow up period less than 5 years were excluded. 
Laser equipment. Diode laser (Ceralas D15) was installed in 1999 for treatment procedures at the outpatient 
department LOC. 980nm laser is gallium-aluminum-arsenide (GaAlAs) laser system with 15W output power and bare 
fiber light delivery (400 or 600 µm). Diode laser was used in continuous or in pulse mode. In pulse mode the pulse 







         Figure 1.  Compact size air-cooled diode laser Ceralas D15 
 
Surgical Technique. The laser surgery was performed under topical (with EMLA cream) or local infiltrative anesthesia 
(with 0,5% solution of lidocaine hydrochloride). Diode laser beam was sent via bare optical fiber. Malignant lesions 
were treated from normal skin around the tumor following from the periphery to the center. We sampled tissue from 
lesion for histological conformation during the operation sometimes. The eyes of the patients and oncologist were 
protected by glasses absorbing diode laser radiation. All patients were treated in a single session on an outpatient 
department. 
4. Results and discussion   
The study considers a group of 167 patients affected by basal-cell carcinoma (BCC) on the nose. 11 patients were 
observed less than 5 years, these were omitted from the research. There were 112 females and 26 males patients. The 
mean age of the cohort was 64.51 years (range 35-91, median 66 years). The average length of the illness was 13 

































Among 162 cases of ВСС residual tumor appears in 7 cases (4,32%); Recurrence rate  was from 4.11% till 33,33%. The 
lowest recurrence rate was observed in cases of superficial BCC, <6mm; bet the highest recurrence rate was in cases of 
infiltrative BCC and nodular recurrent BCC.  
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BCC recurrence rate varied according histological subtype and localization. Among 162 cases of ВСС the lowest 
recurrence rate  ascertained  in cases of superficial BCC, localization on “body of nose”; the highest - in cases of 
infiltrative BCC, localization on “body of nose” (there are no data about other localization) and nodular recurrent BCC 
localization on “fossa nasolabialis”. 
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pBCC  4 (10,00%) 0 0 2 (50%) 
 





pBCC  6 (19,35 %) 2 (28,57 % ) 2 (33,33) 2 (50%) 
 






pBCC  4 (100%) * * * 
 
rBCC 3 (100%) * * * 
                                                                                                                                        * - no cases 
 
In our study population there were no postoperative complications such as pain, bleeding, inflammation. Mean wound 
healing was from 7 to 10 days. All patients were satisfied with the laser treatment procedure and the results after surgery. 








 980nm laser shows high efficiency in difficult-to treat BCC in nose region. The given data allows to conclude that laser 
treatment is most effective in cases of primary superficial BCC, nodular BCC and recurrent superficial BCC, diameter 
<6mm, located on body of nose. Laser surgery is not effective in any form of infiltrative BCC. In cases of recurrent 
nodular BCC the decision about laser surgery must be discussed.  Diode laser is useful tool in dermatology with good 
acceptance by the patients and good cosmetics results. However, not for all BCC on the nose laser treatment is the most 
efficient way of treatment. Therefore additional research has to be carried out, in order to find the most appropriate 
treatment method. Future prospective comparative randomized studies with diode laser are needed. 
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